Caelyx [doxorubicin liposomal] biweekly in heavily pretreated patients with relapsed ovarian cancer.
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2017
At a glance
- Drugs Doxorubicin liposomal (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 28 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Nov 2005 New trial record.